Blue Jet Healthcare Limited raises Rs 800 crore via QIP allotment

Blue Jet Healthcare raised Rs 800 crore through a qualified institutional placement during the quarter ended September 30, 2026, allotting 1,58,10,276 equity shares at Rs 506 each. The issue increased paid-up equity share capital to Rs 37.855 crore from Rs 34.693 crore at March 31, 2026, while financing cash inflow was Rs 752.965 crore after issue-related expenses and other financing items.

How much did Blue Jet Healthcare raise through the QIP?

Blue Jet Healthcare raised gross proceeds of Rs 800 crore through a qualified institutional placement, or QIP, during the quarter ended September 30, 2026. The company allotted shares to eligible qualified institutional buyers, or QIBs, under the Securities and Exchange Board of India Issue of Capital and Disclosure Requirements Regulations.

The issue involved 1,58,10,276 equity shares of face value Rs 2 each, issued at Rs 506 per share. The issue price included a premium of Rs 504 per share, meaning Rs 800 crore was the aggregate amount raised rather than the increase in face-value share capital. Blue Jet Healthcare disclosed the allotment in financial results approved by its board on November 5, 2026.

The six-month cash-flow statement records Rs 800 crore of QIP proceeds and Rs 19.387 crore of share-issue expenses for the period ended September 30, 2026. The filing does not specify the intended use of the QIP proceeds or identify the QIBs that received the shares.

How did the QIP change Blue Jet Healthcare’s share capital?

Blue Jet Healthcare’s paid-up equity share capital rose by Rs 3.162 crore to Rs 37.855 crore at September 30, 2026, from Rs 34.693 crore at March 31, 2026. That increase corresponds to the Rs 2 face value on the 1,58,10,276 shares allotted through the QIP.

The issue premium explains why the Rs 800 crore QIP amount was far larger than the Rs 3.162 crore increase in stated share capital. Other equity was Rs 2,260.738 crore at September 30, 2026, compared with Rs 1,325.219 crore at March 31, 2026, while total equity increased to Rs 2,298.593 crore from Rs 1,359.912 crore.

The company reported basic and diluted earnings per share of Rs 10.00 for the six months ended September 30, 2026, compared with Rs 8.26 a year earlier. Blue Jet Healthcare stated that earnings per share for interim periods are not annualised.

How did Blue Jet Healthcare’s balance sheet change after the QIP?

Blue Jet Healthcare reported total assets of Rs 2,583.878 crore at September 30, 2026, up from Rs 1,641.158 crore at March 31, 2026. The Rs 942.720 crore increase broadly tracked the Rs 938.681 crore rise in total equity over the same six-month period.

Current investments increased to Rs 604.601 crore from Rs 226.697 crore, and other balances with banks rose to Rs 324.876 crore from Rs 88.014 crore. Cash and cash equivalents increased to Rs 76.727 crore from Rs 60.857 crore, showing that the changed asset mix included investments and bank balances as well as cash.

Capital work in progress rose to Rs 357.868 crore at September 30, 2026 from Rs 301.376 crore at March 31, 2026. Inventories also increased to Rs 251.257 crore from Rs 187.389 crore, while trade receivables were Rs 444.652 crore compared with Rs 339.046 crore at the March 2026 year-end.

What were Blue Jet Healthcare’s September-quarter results?

Blue Jet Healthcare reported revenue from operations of Rs 375.744 crore for the three months ended September 30, 2026, compared with Rs 293.113 crore in the preceding June 2026 quarter and Rs 165.481 crore in the September 2025 quarter. Profit after tax was Rs 102.517 crore, versus Rs 78.264 crore in June 2026 and Rs 52.136 crore a year earlier.

For the six months ended September 30, 2026, revenue from operations was Rs 668.857 crore, against Rs 520.239 crore in the comparable 2025 period. Profit after tax increased to Rs 180.781 crore from Rs 143.307 crore, while profit before tax rose to Rs 243.340 crore from Rs 191.587 crore.

Blue Jet Healthcare identified one reportable business segment under Indian Accounting Standard 108: manufacturing artificial sweetener, contrast media intermediate, pharmaceutical intermediate and active pharmaceutical ingredients, or APIs, used in pharmaceutical and healthcare products. The filing also states that Blue Jet Healthcare had no subsidiaries, associates or joint ventures as of September 30, 2026, so consolidated financial statements were not applicable.

How did Blue Jet Healthcare’s cash flows move in the first half?

Blue Jet Healthcare used Rs 25.612 crore in operating activities in the six months ended September 30, 2026, compared with Rs 207.187 crore generated in the six months ended September 30, 2025. The cash-flow statement reported operating profit before working-capital changes of Rs 231.189 crore in the 2026 period, compared with Rs 191.149 crore a year earlier.

Investing activities used Rs 711.484 crore in the 2026 half year, compared with Rs 164.632 crore in the prior-year period. Purchases of investments were Rs 672.788 crore and purchases of property, plant, equipment and intangible assets were Rs 76.139 crore, while current investments rose by Rs 377.904 crore on the balance sheet.

Financing activities generated Rs 752.965 crore during the six months ended September 30, 2026, compared with an outflow of Rs 8.536 crore a year earlier. The QIP generated Rs 800 crore before Rs 19.387 crore of issue expenses, and cash and cash equivalents ended the period at Rs 76.727 crore.

Conclusion

The September 2026 QIP added Rs 800 crore of gross proceeds and 1,58,10,276 new equity shares to Blue Jet Healthcare’s capital structure at Rs 506 per share. Over the six months from March 31, total equity increased by Rs 938.681 crore and total assets by Rs 942.720 crore, with current investments and bank balances rising alongside the equity raise.

The next point to watch is how Blue Jet Healthcare’s future filings explain movements in its Rs 604.601 crore current-investment balance, Rs 357.868 crore capital work-in-progress balance and Rs 324.876 crore other bank balances. The November 5, 2026 filing does not disclose a specific use-of-proceeds plan, capital-raising target or further timetable related to the QIP.